Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

  • Revenue in USD (TTM)63.17bn
  • Net income in USD12.15bn
  • Incorporated1970
  • Employees72.00k
  • Location
    Merck & Co Inc126 East Lincoln AvenueRAHWAY 07065United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttps://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Modifi Biosciences IncDeal completed23 Oct 202423 Oct 2024Deal completed-3.49%1.33bn
Unity Semiconductor SasAnnounced18 Jul 202418 Jul 2024Announced-18.25%--
Eyebiotech LtdDeal completed29 May 202429 May 2024Deal completed-18.38%3.00bn
Abceutics IncDeal completed05 Apr 202405 Apr 2024Deal completed-19.38%208.00m
Caraway Therapeutics IncAnnounced21 Nov 202321 Nov 2023Announced0.23%610.00m
Data delayed at least 15 minutes, as of Nov 08 2024 21:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.